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S_ary Incubation of CCRF CEM C7A human lymphoblastic leukaemia cells with etoposide (VP16) or
N-methylformamide (NMF) induced apoptotic cell death. The kinetics of onset of apoptosis was determined
and compared with that for dexamethasone-treated cells. The drugs induced 50% apoptosis at different rates:
etoposide by approximately 18 h, NMF by 40 h and dexamethasone (DEX) by 52 h. In each case, the onset of
apoptosis above 10% was preceded by a delay period. This was 8 h for etoposide, between 8 and 12 h for
NMF and 36 h for dexamethasone. When cells were incubated for 36 h with dexamethasone and the drug
washed out, addition of NMF induced apoptosis without any delay, suggesting that certain common
biochemical events are required to prime the cells for apoptosis. However, cells treated for 8 h with NMF did
not undergo immediate apoptosis on the addition of DEX. Analysis of the cellular content of the c-mic
protein showed this to be undetectable by 2. 6 and 12 h after treatment with etoposide, NMF and DEX
respectively. The rapid onset of NMF-induced cell death after a 36 h DEX pretreatment occurred 24 h after
the loss of expression of c-Myc protein, suggesting that the expression of c-mwc is not required for
drug-induced cell death. In contrast to DEX-induced apoptosis. concomitant incubation of cells with NMF or
etoposide and 200 nm of the protein synthesis inhibitor cycloheximide did not inhibit apoptotic cell death. The
idea that drugs with different modes of action initiate conserved responses which engage a programmed cell
death is disussed.
Keyword: apoptosis; dexamethasone: N-methylformamide; etoposide (VPl6); c-myc; CCRF CEM human
leukaemia cells
There have been many reports of the induction of apoptosis
by anti-cancer drugs in susceptible cells (reviewed by Hick-
man, 1992; Sen and D'Incalci, 1993; Dive and Wyllie, 1993;
Eastman, 1993). Drugs with very disparate mechanisms of
action initiate this conserved cellular response, characterised
in plasma membrane-intact cells by a condensation of
chromatin and the appearance of higher order chromatin
fragments and/or 200 bp integer internucleosomal fragments
(Wylie, 1980; Oberhammer et al., 1993). The initiation of
this conserved cellular response suggests that events which
are downstream of the immediate actions of the drugs, such
as the inhibition of topoisomerase II and induction of DNA
double-strand breaks by etoposide, couple either perturba-
tions in cellular metabolism or cellular damage to the engage-
ment of apoptosis (Dive and Hickman, 1991). The nature of
these coupling events is not well defined, nor is it known
what shared features, such as changes in gene expression,
may be necessary for the initiation of apoptosis by different
drugs. It is important that these be understood as it is
probable that much of the clinically relevant drug resistance
may be the result of cellular attenuation of the apoptotic
response to pharmacological perturbations (Hickman et al.,
1994).
It has been proposed recently that deregulated expression
of the c-myc oncogene may promote apoptosis in certain
cells, including those of myeloid lineage and primary fibro-
blasts (Askew et al., 1991; Evan et al., 1992). However,
dexamethasone (DEX) was reported to bring about a reduc-
tion of c-myc mRNA (Yuh and Thompson, 1989) and pro-
tein (Wood et al., 1994) before the apoptosis of the lymphob-
lastoid cell line CCRF CEM C7A. This suggests that these
cells do not die because of the continued expression of c-myc
under conditions of pharmacologically imposed limited
growth. It was argued, on the basis of experiments using
transient transfections of c-myc, that the suppression of ex-
pression was necessary for DEX-induced death of these cells
(Thulasi et al., 1993). Measurement of changes in c-myc
expression and the kinetics of apoptosis induced by agents
with different cellular targets was therefore considered to be
of interest. DEX, a transcriptional modulator, has been the
subject of a number of studies of the molecular mechanisms
of apoptosis and induces a G, block in CCRF lymphoblastic
leukaemia cells (Harmon et al., 1979; Wood et al., 1994); the
kinetics of apoptosis induced by continuous incubation with
DEX was characterised by a 36 h lag phase before the onset
of apoptosis, which we designated the priming phase (Wood
et al., 1994). Etoposide is a topoisomerase II inhibitor which
induces transient DNA double-strand breaks (Liu, 1989) and
N-methylformamide (NMF) is a cytotoxin which, like DEX,
inhibits passage through the cell cycle at the GI phase (Bill et
al., 1988) and is considered to have the plasma membrane as
an important locus ofaction (Dibner et al., 1985). The results
of the present study suggest that apoptosis induced by these
three mechanistically disparate agents has certain features in
common. However, on the basis of the data it is suggested
that changes in the expression of the c-myc proto-oncogene
are incidental to drug-induced apoptotic cell death.
Materials and method
Materials
All materials were purchased from Sigma (Poole, UK), unless
stated otherwise. The CT9 antibody to human c-Myc protein
was a generous gift from Gerard Evan (ICRF, London, UK).
Cell culture
The T-cell lymphoblastic leukaemia cell line CCRF CEM
C7A was kindly donated by Dr E Brad Thompson, The
University of Texas, Galvaston, TX, USA. This
glucocorticoid-sensitive cell line was originally cloned and
characterised by Norman and Thompson (1977). Cells were
grown as a suspension in RPMI-1640 medium supplemented
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with 10% fetal calf serum (Applied Protein Products, Lewes,
Sussex, UK). Cultures were incubated at 37C in a
humidified atmosphere of 5% carbon dioxide and discarded
after 30 subcultures to prevent phenotypic drift.
Drug treatment
Approximately 2 x I0 cells ml-' in the logarithmic phase of
cell growth were exposed to various agents for the times
noted. Agents were dissolved in absolute ethanol and
dimethylsulphoxide (DMSO) the final volume of which was
not greater than 0.1%. Control cultures received the solvent
alone.
Measurement ofcell integrity and apoptosis
Cell membrane integrity was measured by the exclusion of a
0.4% solution of trypan blue. Apoptosis was measured by
addition (1:1) of a solution of lI0Lgml'- acridine orange
(Molecular Probes, Eugene, OR, USA) and an apoptotic cell
was scored as positive when cell membrane integrity was
maintained and chromatin was condensed, as previously des-
cribed in detail (Wood et al., 1994). In triplicate experiments,
more than 200 cells were scored on each occasion.
Estimation ofDNA integrity byfield inversion gel
electrophoresis
This was performed essentially as described previously (Ober-
hammer et al., 1993). Cells were washed three times with pre-
warmed phosphate-buffered saline (PBS) and centrifuged at
170g for 5min. A pellet of 106 cells was resuspended in
100 I of molten 1% low melting point (LMP) agarose
prepared in PBS, and set into plugs using a Perspex mould.
The plugs were incubated at 50°C for 24 h in I ml of L buffer
(0.1 M EDTA pH 8.0, 0.01 M Tris-CI pH 7.6, 0.02 M sodium
chloride) containing I mgml-' pronase. The plugs were
washed twice for 2 h in L buffer. Before electrophoresis the
plugs were equilibrated in 10 mM Tris-EDTA (pH 8.0). The
plugs were sealed into a 1.5% gel with 1% LMP agarose.
Lambda ladder markers ranging from 50 to 1000 kb and
yeast artificial chromosome fragments were used as molecular
weight standards. The electrophoresis was performed for 24 h
at 150V in 0.5 xTris acetate, 1mM EDTA, with a pulse
time of 65 s using a Waltser II horizontal gel chamber
(Tribotics). The gel was stained with ethidium bromide and
viewed under ultraviolet light.
Western blotting
Proteins were separated using SDS-PAGE and elec-
trophoretically transferred to nitrocellulose filters (Hybond
extra-C, Amersham, UK) by the method of Towbin et al.
(1979). Immunoblotting was performed using the monoclonal
mouse-antihuman antibody CTI9 raised to a peptide of the
C-terminal end of the c-Myc protein (Evan et al., 1985).
Peroxidase-conjugated secondary antibodies were incubated
with the blots for I h before visualising the proteins by use of
an enhanced chemiluminescence system (Amersham, UK).
Results
Induction ofapoptosis by drugs
Concentration-response relationships were established for
each agent (data not shown) and a kinetic analysis of cell
death was then performed with a drug-concentration-induced
maximum apoptosis with minimal loss of membrane integ-
rity. Analysis of DNA integrity by field inversion gel elec-
trophoresis showed the appearance of higher order chromatin
fragments (Figure 1). typical of apoptosis (Oberhammer et
al., 1993). Figure 2a-c shows the percentage apoptosis in
CEM C7A cells incubated continuously with 5gLM etoposide,
270 mM NMF or 5IlM DEX respectively. The last result
Figwe 1 Field inversion gel electrophoresis of DNA from
CCRF CEM C7A cells treated as follows: M and Y = A ladder
and yeast artificial chromosome fragment molecular weight
markers respectively; C = control. DEX: I = 48 h, 2 = 54h,
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Fiure 2 The percentage of apoptotic CEM C7A cells, measured
by acridine orange (AO) staining (U) and those unable to ex-
clude the vital dye trypan blue (TB) (0) after continuous incuba-
tion with (a) etoposide 5;Lm, (b) N-methylformamide 270 mM or
(c) dexamethasone 5 yMi (n = 3;±s.d.; *** P<0.005, ** P<0.01).
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I Iconfirms our previous data (Wood et al., 1994). Each agent
showed a lag phase before the onset of cell death, although
that for NMF was not as well defined as for the other two
agents. Rather, there was a gradual rise in the number of
apoptotic cells after 8 h (Figure 2). The time of onset of
apoptosis and the rate of the subsequent rise in the numbers
ofapoptotic cells was different for each agent. The lag phases
were 8 h for etoposide, between 8 and 12 h for NMF and
36 h for DEX. Removal of etoposide before 4 h and NMF
before 8 h, followed by washing, prevented any subsequent
apoptosis (data not shown). We had previously shown that
removal of DEX before 36 h prevented the engagement of
apoptosis (Wood et al., 1994). The control cultures main-
tained >95% membrane intact cells, with <8% apoptosis
until after 72 h, when cell number plateaued at approx-
imately 2 x 106 m.' (Wood et al., 1994).
Expression ofc-myc before apoptosis
One of the changes in gene expression observed during DEX-
induced lag phase was the decrease of the c-myc proto-
oncogene (Yuh and Thompson, 1989). The expression of the
c-Myc protein, measured by Western blotting, during the
continuous incubation with etoposide and NMF is shown in
Figure 3. The loss of c-Myc protein preceded the appearance
of apoptotic cells in all cases, with kinetics which reflected
the order of the time of onset of cell death (see Figure 2).
Induction ofapoptosis after a primingperiod
Because each of the agents induced apoptosis after a lag
phase (Figure 2), it was of interest to determine whether
some of the events which occurred in this phase were com-
mon to each agent. If so, it would be predicted that when the
initiating stimulus was withdrawn, just before the onset of
apoptosis and a different agent added, apoptosis might be
initiated without delay. The results are shown in Figure 4 for
experiments with NMF and DEX. These two agents were
used because their lag phases are very significantly different,
whereas we considered that those between etoposide and
NMF were similar enough to give rise to potentially
equivocal results regarding changes in the timing of the onset
of apoptosis. Incubation with DEX for 36 h, followed by
washing before the addition of NMF, induced a rapid
engagement of apoptosis. It had previously been shown that
the removal of DEX at 36 h prevents apoptosis thereafter
(Wood et al., 1994). The prior treatment with DEX therefore
circumvented the delay before NMF-induced apoptosis
(Figure 4). However, when the experiment was performed in
reverse, with an 8 h NMF preincubation before the addition
of DEX (after removal of NMF), an immediate onset of
apoptosis was not observed (Figure 4). Rather, the kinetics
of the onset of apoptosis resembled that of DEX alone.
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pound itself inducing apoptosis (Wood et al., 1994). The
results of coincubation of NMF or etoposide with varying
concentrations of cycloheximide are shown in Figure 5. In
comparison with our previous study (Wood et al., 1994), in
which cycloheximide inhibited DEX-induced apoptosis, it
had no effect on NMF or etoposide-induced cell death.
Dioass
The disparate nature of the triggering events for apoptosis,
ranging from trophic factor withdrawal to the imposition of
a variety of types ofcellular damage, might be expected to be
integrated at some point so as to activate conserved pro-
cesses, such as DNA cleavage, which as effectors commit the
cell to an apoptotic death. Novel strategies to initiate apop-
tosis in tumour cells should be targeted at these integrated
effector events, where presumably gene products such as
Bcl-2 might act to inhibit apoptosis triggered by many
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Fuwe 4 The percentage apoptosis with tiue in CEM C7A cells
treated with ( + ) dexamethasone 5 FLM continuously for 48 h (*)
dexamethasone for 36 h followed by 270 mm N-methylformamide
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Figwe 3 Western blot of c-Myc protein after continuous treat-
ment of CEM C7A cells with (a) 5pum etoposide or (b) 270mnm
N-methylformamide (as in Figure 1).
Fiwe 5 The percentage apoptosis of cells treated continuously
with varying concentrations of cyclobeximide and (a) 5jLM
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stimuli, includingall classes of anti-tumour drugs (Reed,
1994). It is therefore important, with respect to drug action,
to discriminate between those events, such as a change in
gene expression, which might be peculiar to a particular drug
and those which might be conserved to all drug classes; these
latter changes are more likely to relate to the integration of
signals arising from cellular damage so as to initiate apop-
tosis. We have attempted such a study here with respect to
changes in the expression of the c-myc oncogene and the
activity of three different drugs: DEX, a transcriptional
modulator, etoposide, a topoisomerase II inhibitor which
induces DNA damage; and NMF, which modulates mem-
brane activity (see introduction).
We had previously shown that continuous treatment of
CCRF CEM C7A cells with 5gM DEX for 36 h is required
before apoptosis is initiated (Wood et al., 1994). It was
argued that this is a priming or precommitment period dur-
ing which changes in gene transcription are occurring that
are necessary for the cells to die subsequently. In support of
this argument is the observation that apoptosis was inhibited
by co-incubation with cycloheximide during the priming
phase. Among the changes observed in this period was a fall
in the expression of c-myc mRNA (Yuh and Thompson,
1989) and protein (Wood et al., 1994). But, by a variety of
experimental manipulations, our data (Wood et al., 1994) did
not support the case for a causative role for c-myc suppres-
sion in DEX-induced apoptosis, in contradiction to the work
of Thulasi et al. (1993). With respect to the experiments
described here, it was interesting that the action of two other
drugs was also characterised by a lag phase before the onset
ofapoptosis (Figure 2), the length of which was proportional
to the rate of disappearance of the c-Myc protein (Figure 3).
This fall did not correspond to an accumulation of the cells
in some discrete part of the cell cycle (Wood et al., 1994, and
data not shown). Additionally, the complete loss of c-myc
expression after etoposide is too rapid to be explained by an
accumulation at some check point in the cell cycle of a cell
type with a 24 h doubling. Because of the close temporal
relationship between the fall in c-Myc protein and the onset
of apoptosis (Figures 2 and 3) it could be suggested that a
fall in c-myc expression is a prerequisite for drug-induced
apoptosis of these cells, as has been proposed for DEX-
induced cell death (Yuh and Thompson, 1989; Thulasi et al.,
1993). However, we have presented data challenging this
idea, showing that cells are not committed to apoptosis when
c-myc expression is attenuated (Wood et al., 1994). We have
attempted to test the hypothesis directly by stable transfec-
tion and expression of c-myc in CCRF CEM C7A cells, using
an inducible promoter, but the experiments resulted in the
death of all c-myc-expressing clones shortly after transfection
(AC Wood et al., unpublished). A drug-induced fall in c-myc
expression has also been observed as a common event in the
treatment of a variety ofcells with different agents, including
NMF, at concentrations which induce both differentiation
and apoptosis (Lachman and Skoultchi, 1984; Yen, 1985;
Mitchell et al.,1992; Beere et al., 1993). Clues as to the
mechanism of this fall in expression may be helpful in
understanding some of the early changes induced in response
to drug-induced damage, even ifchanges in c-myc expression
do not play a causative role in the apoptosis of CEM C7A
cells.
The other point to note regarding the c-myc proto-
oncogene is that its continued expression is not necessary for
the induction of apoptosis of CCRF CEM C7A cells (Figure
4). This is different from suggestions arising from the work of
Evan et al. (1992) and others, who have artefactually over-
expressed this gene and have implied that its expression can
directly or indirectly play a role in the regulation of apop-
tosis. In cells in which c-Myc protein had been lost for a full
24 h (after DEX treatment) NMF was able to induce rapid
and high levels of apoptosis. It could be argued that the
expression of c-myc in a dividingcell primes it in some way
for apoptosis, and that its continued expression at the time of
actual commitment is not necessary. However, under the
conditions used here, DEX-treatedcells continue to progress
over 24h for a full cell cycle without c-myc expression
(Wood et al., 1994) so that, unless some c-myc transcription-
dependent, long-lived protein(s) such as endonucleases or
proteases are completely stable for this full cell cycle, it seems
reasonable to suggest that changes in the expression of c-myc
are not causative but rather only correlative with the com-
mitment of CCRF CEM C7A cells to apoptosis and, cer-
tainly, that continued expression of the gene does not play a
role in drug-induced apoptosis.
The idea that there are common events initiated by
different stimuli for apoptosis is supported by the findings
shown in Figure 4: prior treatment of the cells with DEX for
apriming period permitted NMF to engagecell death almost
immediately, removing the delay associated with NMF-
induced apoptosis (Figure 2). However, we expected that the
experiment might work in reverse, that is that NMF primed
cells might die as soon as DEX was added. That there was a
delay of at least 36 h suggests that there are differences in the
way that these agents ultimately initiate apoptosis,
presumably with DEX requiring some drug-speific, tran-
scriptionally dependent production of a trigger of the apop-
totic response. Our current experiments seek to discover
whether these aredifferencesin the qualitative, quantitative
or temporal patterns of changes in gene expression during
the priming period. But, because we found that cyclohex-
imide, at a non-toxic concentration, did not inhibit cell death
induced by either VP16 or NMF (Figure 5), the concept that
each of these agents induces new gene expression is ques-
tionable. In the case of etoposide, evidence from p53 null
thymocytes suggests that apoptosis is a p53-dependent pro-
cess (Clarke et al., 1993) and, since p53 is a transcriptional
regulator, it might be expected that p53-initiated gene expres-
sion would be required for the engagement of apoptosis
(Lane, 1993). However, a recent report has suggested that
transcriptional events are not necessary for DNA damage-
induced p53-driven apoptosis but, rather, that a transcrip-
tionalrepresson of a survival gene may initiate apoptosis
(Caelles et al., 1994). Experiments with cycloheximide are
difficult to interpret however. although we showed that syn-
thesis of the short half-life protein c-Myc was inhibited under
these conditions (Wood et al., 1994), the toxicity per se of
cycloheximide does not allow the concentration to be in-
creased so that all protein synthesis was blocked, a criticsm
which is also apposite to the work of Caelles et al. (1994).
Moreover, it is possible that the important, common integral
event for the initiation of apoptosis is one of the suppression
of gene expression. The inhibition of DEX-induced apoptosis
by cycloheximide (Wood et al., 1994) might then be
explained by a failure to synthesise some key component
iecessary to initiate a subsequent suppression of gene expres-
sion, presumably of a gene of vital importance to the
maintenance of viability. Such a hypothesis is under inves-
tigation, using the methods of subtractive hybridisation.
Comparison and subtraction of patterns of gene expression
during the lag phase, before the onset of apoptosis initiated
by different drugs, might provide discriminatory information
relating to both drug-specific and common changes responsi-
ble for the engagement of apoptosis.
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